Dutch biotech Azafaros gains €132M series B to fund phase 3 trials of brain-penetrant drug
Azafaros has secured 132 million euros ($147 million) in series B funds that the Dutch biotech will use to push its brain disease drug through two late-stage trials.
Azafaros has secured 132 million euros ($147 million) in series B funds that the Dutch biotech will use to push its brain disease drug through two late-stage trials.
